The month ahead: March's upcoming events
Another SERD catalyst and the son of Darzalex take centre stage.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
